Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis

Condition:   Prostate Carcinoma Metastatic to the BoneInterventions:   Drug: Enzalutamide;   Radiation: Radium ra 223 dichlorideSponsors:   Carolina Research Professionals, LLC;   Astellas Pharma IncNot yet recruiting - verified July 2015

Source: ClinicalTrials.gov - July 16, 2015 Category: Research Source Type: clinical trials